Frank P. Zemlan

Chief Executive Officer at Phase 2 Discovery, Inc.

Health Technology

Consumer Services

Profile

Frank P.
Zemlan is Chief Executive Officer of Phase 2 Discovery, Inc. He has over 20 years of experience in clinical research at Merck & Co., Inc., Aventis, Inc., and GlaxoSmithKline Plc.
Dr. Zemlan holds a PhD.

Frank P. Zemlan active positions

Companies	Position	Start
Phase 2 Discovery, Inc. Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.	Chief Executive Officer	-

All active positions of Frank P. Zemlan

Former positions of Frank P. Zemlan

Companies	Position	End
Aventis, Inc.	Corporate Officer/Principal	-
GSK PLC	Corporate Officer/Principal	-
MERCK & CO., INC.	Corporate Officer/Principal	-

See the detail of Frank P. Zemlan's experience

Training of Frank P. Zemlan

Villanova University	Graduate Degree
University of Pennsylvania	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Frank P. Zemlan's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
MERCK & CO., INC.	Health Technology
GSK PLC	Health Technology

Private companies	2
Phase 2 Discovery, Inc. Phase 2 Discovery, Inc. Pharmaceuticals: MajorHealth Technology Phase 2 Discovery, Inc. (P2D) develops central nervous system drugs. The company provides discovery research & development services for pharmaceutical and biotechnology companies. It also develops drugs for treating psychiatric and neurologic disorders. Its products include PD6735, the treatment of primary insomnia and additional indications, N-Substituted Analogs of Benztropine for the treatment of attention deficit hyperactivity disorder & Thiothalidomides and Hydroxythalidomides for the treatment of ALS and MS. Phase 2 Discovery was founded in 1998 and is headquartered in Cincinnati, OH.	Health Technology
Aventis, Inc.